1. Shestakova, M.V. and Vikulova, O.K., Modern pharmacotherapy of type 2 diabetes using analogues of glucagon-like peptide-1 (GLP-1), Sakharnyi Diabet, 2007, no. 1, p. 9.
2. Holst, J.J., Deacon, C.F., Vilsboll, T., et al., Glucagon-like peptide-1, glucose homeostasis and diabetes, Trends Mol. Med., 2008, vol. 14, no. 4, p. 161.
3. Galstyan, G.R., Karataeva, E.A., and Yudovich, E.A., Evolution of glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes, Sakharnyi Diabet, 2017, vol. 20, no. 4, p. 286.
4. Biryukova, E.V. and Yakubova, T.R., Byetta: past, present, and future, Eff. Farmakoter., 2015, no. 11, p. 34.
5. Gallwitz, B., Novel therapeutic approaches in diabetes, Endocrinol. Dev., 2016, vol. 31, p. 43.